Financial Services

With over 99% creditor approval, Advantage Solutions restructures its debt, gaining time but facing higher costs and a skeptical stock market.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

The Chicago-style chain posts declining same-store sales and a 40% drop in annual profit, pinning turnaround hopes on a new CEO and strategic slowdown.

An InsurTech spin-off is slashing costs and speeding up agent onboarding, setting a new benchmark for a legacy industry resistant to change.

The D.C.-based wood-fired pizza favorite is expanding into Virginia's competitive market, betting on a hot franchise climate and its neighborhood recipe.

Facing SEC delays, Aptose Biosciences secures an $11.1M lifeline from its acquirer, Hanmi, highlighting financial strain as the critical deal moves forward.

The bioprocessing leader posted robust 2025 earnings, outperforming the market with strategic innovation and a major expansion into Asian markets.

Facing delisting, Hong Kong-based PTL Limited enacts a massive 1-for-80 share consolidation. But can this financial maneuver fix deeper business issues?

The partnership moves beyond compliance, integrating deep binary analysis with lifecycle management to provide continuous software risk intelligence for critical industries.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

Penske Automotive's latest Florida acquisition highlights a fierce battle for the state's booming luxury car market, adding $450M in expected revenue.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

As Ring Energy preps its Q4 results, investors eye debt reduction, cost control, and 2026 strategy amid a challenging Permian market.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

The shipping and printing giant's spot on a top global list highlights a stable model for entrepreneurs and its vital role in supporting small businesses.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

Life Time posts record 2025 earnings and a 230% Q4 profit surge, announcing a $500M share buyback and an aggressive expansion of its 'athletic country clubs'.

Planet Fitness reports a 12.1% revenue surge and adds 1.1 million members, proving its model's resilience even as Wall Street weighs future growth.

Singapore's OUE REIT makes a strategic A$357M entry into Australia, acquiring a stake in Sydney's prime, green-certified Salesforce Tower.